WO2003039598A8 - Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain - Google Patents
Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and painInfo
- Publication number
- WO2003039598A8 WO2003039598A8 PCT/US2002/035396 US0235396W WO03039598A8 WO 2003039598 A8 WO2003039598 A8 WO 2003039598A8 US 0235396 W US0235396 W US 0235396W WO 03039598 A8 WO03039598 A8 WO 03039598A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syndrome
- pain
- serotonin reuptake
- reuptake inhibitors
- selective norepinephrine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02793880A EP1463528B1 (en) | 2001-11-05 | 2002-11-05 | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain |
AT02793880T ATE552856T1 (en) | 2001-11-05 | 2002-11-05 | SELECTIVE NOREPINEPHRINE-SEROTONIN REUPPOST INHIBITORS FOR THE TREATMENT OF FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN |
CA002467356A CA2467356C (en) | 2001-11-05 | 2002-11-05 | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
ES02793880T ES2395462T3 (en) | 2001-11-05 | 2002-11-05 | Selective norepinephrine-serotonin reuptake inhibitors for the treatment of fibromyalgia syndrome, chronic fatigue syndrome and pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/014,149 | 2001-11-05 | ||
US10/014,149 US6635675B2 (en) | 2001-11-05 | 2001-11-05 | Method of treating chronic fatigue syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003039598A1 WO2003039598A1 (en) | 2003-05-15 |
WO2003039598A8 true WO2003039598A8 (en) | 2004-06-03 |
Family
ID=21763814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/035396 WO2003039598A1 (en) | 2001-11-05 | 2002-11-05 | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain |
Country Status (7)
Country | Link |
---|---|
US (1) | US6635675B2 (en) |
EP (2) | EP2322225B1 (en) |
AT (1) | ATE552856T1 (en) |
CA (1) | CA2467356C (en) |
ES (2) | ES2433080T3 (en) |
PT (2) | PT2322225E (en) |
WO (1) | WO2003039598A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070117869A1 (en) * | 2000-11-01 | 2007-05-24 | Cognition Pharmaceuticals Llc | Methods for treating coginitive impairment and improving cognition |
US20050059743A1 (en) * | 2000-11-01 | 2005-03-17 | Sention, Inc. | Methods for treating mild cognitive impairment and alzheimer's disease |
WO2005000203A2 (en) * | 2001-10-31 | 2005-01-06 | Sention, Inc. | Methods for treating cognitive impairment and improving cognition |
US7619005B2 (en) * | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
US20030232890A1 (en) * | 2000-11-01 | 2003-12-18 | Sention, Inc. | Methods for treating an impairment in memory consolidation |
US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
AU2003213009A1 (en) * | 2002-02-12 | 2003-09-04 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
CN1671368A (en) * | 2002-07-24 | 2005-09-21 | 柏树生物科学公司 | Treatment of depression secondary to pain (DSP) |
MXPA05001705A (en) * | 2002-08-14 | 2005-04-19 | Pharmacia & Upjohn Co Llc | Use of reboxetine for the treatment of hot flashes. |
MXPA05003550A (en) * | 2002-10-03 | 2006-01-24 | Cypress Bioscience Inc | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders. |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
EP1572187A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
FR2851163B1 (en) * | 2003-02-14 | 2007-04-27 | USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
BRPI0407256A (en) * | 2003-02-14 | 2006-01-31 | Pf Medicament | Use of the milnacipran enantiomer (1s, 2r) for the preparation of a medicament |
CA2538412A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
EP1745029A1 (en) * | 2004-04-30 | 2007-01-24 | Warner-Lambert Company LLC | Substituted morpholine compounds for the treatment of central nervous system disorders |
WO2006081518A2 (en) * | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
US7956050B2 (en) | 2005-07-15 | 2011-06-07 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
WO2008009663A1 (en) * | 2006-07-19 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Treatment of pain |
EP2114868A2 (en) * | 2007-02-28 | 2009-11-11 | Ranbaxy Laboratories Limited | Novel polymorphic forms of milnacipran hydrochloride |
JP2010043063A (en) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
FR2944011B1 (en) | 2009-04-03 | 2011-05-20 | Pf Medicament | AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS. |
WO2010129689A1 (en) * | 2009-05-05 | 2010-11-11 | Forest Laboratories Holdings Limited | Milnacipran formulations |
JP5739415B2 (en) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S) -7-([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline Crystal forms and uses thereof |
DK2429296T3 (en) | 2009-05-12 | 2018-03-12 | Albany Molecular Res Inc | 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof |
CA2779711C (en) * | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
WO2012024397A2 (en) | 2010-08-17 | 2012-02-23 | Albany Molecular Research, Inc. | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
FR2978350B1 (en) | 2011-07-28 | 2013-11-08 | Pf Medicament | LEVOMILNACIPRAN-BASED MEDICINAL PRODUCT FOR FUNCTIONAL REHABILITATION AFTER ACUTE NEUROLOGICAL ACCIDENT |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2508035A1 (en) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | ARYL-1-AMINOMETHYL-2 CYCLOPROPANES CARBOXAMIDE (Z) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
IT1188212B (en) | 1985-12-20 | 1988-01-07 | Paolo Colombo | SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES |
US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
FR2640972B1 (en) | 1988-12-28 | 1991-04-19 | Pf Medicament | |
IT1237904B (en) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES |
CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
US5603956A (en) | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
GB9215043D0 (en) | 1992-07-15 | 1992-08-26 | Flow Inc K | Fluid mass flow meters |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5397574A (en) | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5399358A (en) | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
WO1995022521A1 (en) | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
JP4157969B2 (en) | 1994-03-18 | 2008-10-01 | スパーナス ファーマシューティカルズ インコーポレイテッド | Emulsified drug delivery system |
US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US6103263A (en) | 1994-11-17 | 2000-08-15 | Andrx Pharmaceuticals, Inc. | Delayed pulse release hydrogel matrix tablet |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
ATE192042T1 (en) * | 1995-08-16 | 2000-05-15 | Lilly Co Eli | POTENTIATION OF SEROTONIN DRUG RESPONSE |
WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
FR2746314B1 (en) | 1996-03-25 | 1998-06-12 | Pf Medicament | PRODUCT CONTAINING MILNACIPRAN AND IDAZOXAN AS A COMBINED PHARMACEUTICAL PREPARATION |
FR2752732B1 (en) * | 1996-08-28 | 1998-11-20 | Pf Medicament | EXTENDED RELEASE GALENIC FORM OF MILNACIPRAN |
WO1998018452A1 (en) | 1996-10-25 | 1998-05-07 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
FR2759906B1 (en) | 1997-02-21 | 2004-06-04 | Pf Medicament | USE OF MILNACIPRAN AND DERIVATIVES THEREOF FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN PSYCHIATRIC DISEASES |
CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
AU7706598A (en) | 1997-05-30 | 1998-12-30 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US5916595A (en) | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
JP2002515435A (en) * | 1998-05-21 | 2002-05-28 | イーライ・リリー・アンド・カンパニー | Combination therapy for treatment of depression |
US6106862A (en) | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6323242B1 (en) * | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
AU3898000A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of neuropathic pain or fibromyalgia |
JP2003506484A (en) | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | Use of compositions for treating or preventing sleep disorders using very low doses of cyclobenzaprine |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
JP2004517112A (en) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | New drug combination |
-
2001
- 2001-11-05 US US10/014,149 patent/US6635675B2/en not_active Expired - Lifetime
-
2002
- 2002-11-05 PT PT100755206T patent/PT2322225E/en unknown
- 2002-11-05 CA CA002467356A patent/CA2467356C/en not_active Expired - Lifetime
- 2002-11-05 EP EP10075520.6A patent/EP2322225B1/en not_active Expired - Lifetime
- 2002-11-05 PT PT02793880T patent/PT1463528E/en unknown
- 2002-11-05 ES ES10075520T patent/ES2433080T3/en not_active Expired - Lifetime
- 2002-11-05 EP EP02793880A patent/EP1463528B1/en not_active Expired - Lifetime
- 2002-11-05 ES ES02793880T patent/ES2395462T3/en not_active Expired - Lifetime
- 2002-11-05 AT AT02793880T patent/ATE552856T1/en active
- 2002-11-05 WO PCT/US2002/035396 patent/WO2003039598A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2467356C (en) | 2008-06-17 |
CA2467356A1 (en) | 2003-05-15 |
US6635675B2 (en) | 2003-10-21 |
ES2395462T3 (en) | 2013-02-12 |
PT2322225E (en) | 2013-11-07 |
ES2433080T3 (en) | 2013-12-09 |
EP1463528A1 (en) | 2004-10-06 |
PT1463528E (en) | 2012-06-27 |
EP1463528B1 (en) | 2012-04-11 |
EP2322225B1 (en) | 2013-07-31 |
ATE552856T1 (en) | 2012-04-15 |
EP2322225A1 (en) | 2011-05-18 |
WO2003039598A1 (en) | 2003-05-15 |
US20030139476A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003039598A8 (en) | Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain | |
WO2001062236A3 (en) | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent | |
WO2004047830A3 (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction | |
PL372372A1 (en) | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes | |
WO2002053140A3 (en) | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents | |
WO2005023179A3 (en) | Combination methods of treating cancer | |
WO2003032914A3 (en) | Methods for treating substance abuse with cholinesterase inhibitors | |
WO2002038142A3 (en) | Serotonergic compositions and methods for treatment of mild cognitive impairment | |
BR0116206A (en) | Yy Peptide and yy Peptide Agonists for Treatment of Metabolic Disorders | |
WO2001081343A3 (en) | Compounds for treating fibromyalgia and chronic fatigue syndrome | |
CA2260943A1 (en) | Formulation of 5-ht agonists | |
WO2004062624A3 (en) | Method of treating nausea, vomiting, retching or any combination thereof | |
HUP0202687A2 (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
WO2002076388A3 (en) | Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside | |
WO2003006893A3 (en) | Methods of inhibiting amyloid toxicity | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
WO2004101742A3 (en) | Protease inhibitors for coronaviruses and sars-cov and the use thereof | |
WO2001041754A8 (en) | Inhibitors of collagen-induced platelet aggregation | |
WO2003068159A3 (en) | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors | |
WO2003039464A3 (en) | Antimuscarinic aerosol | |
CA2427814A1 (en) | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders | |
WO2001092274A3 (en) | Naaladase inhibitors for treating retinal disorders and glaucoma | |
WO2003065970A3 (en) | Treatment of fibromyalgia and related fatigue syndromes using pindolol | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
WO2003035046A3 (en) | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: EXCEPT/SAUF US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002793880 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2467356 Country of ref document: CA |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 20/2003 UNDER (81) ADD "US"; AS A CONSEQUENCE REPLACE "(71) APPLICANT" BY "(71) APPLICANT (FOR ALL DESIGNATED STATES EXCEPT US)" AND REPLACE "(72) INVENTORS" BY "(72) INVENTORS; AND (75) INVENTORS/ APPLICANTS (FOR US ONLY)"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 2002793880 Country of ref document: EP |